Children with viral-induced wheeze often receive oral or inhaled corticosteroids or a leukotriene inhibitor despite a lack of good evidence that they work. Three studies shed light on this condition.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), reports an update on the Phase III SKYSCRAPER-01 study, evaluating tiragolumab co ...